Penta-Valproic en es it fr

Penta-Valproic Brand names, Penta-Valproic Analogs

Penta-Valproic Brand Names Mixture

  • No information avaliable

Penta-Valproic Chemical_Formula

C8H16O2

Penta-Valproic RX_link

http://www.rxlist.com/cgi/generic2/depakene.htm

Penta-Valproic fda sheet

Penta-Valproic msds (material safety sheet)

Penta-Valproic MSDS

Penta-Valproic Synthesis Reference

Oberreit, Ber.29, 1998 (1896)

Penta-Valproic Molecular Weight

144.211 g/mol

Penta-Valproic Melting Point

120 - 130 oC

Penta-Valproic H2O Solubility

Slightly soluble (1.3 mg/mL)

Penta-Valproic State

Solid

Penta-Valproic LogP

2.549

Penta-Valproic Dosage Forms

Capsule (250 mg); Syrup (250 mg drug/5mL syrup)

Penta-Valproic Indication

For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.

Penta-Valproic Pharmacology

Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.

Penta-Valproic Absorption

Rapid absorption from gastrointestinal tract.

Penta-Valproic side effects and Toxicity

Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.

Penta-Valproic Patient Information

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Penta-Valproic Organisms Affected

Humans and other mammals